CareDx Reports Second Quarter 2017 Financial Results

Published: Aug 11, 2017

BRISBANE, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the second quarter ended June 30, 2017.

Recent highlights:

Achieved total revenue for the second quarter of 2017 of $12.0 million

Back to news